Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy

Clinical Cancer Research

Volumn 5, Issue 1, 1999, Pages 43-50

  Rancourt, Claudine ^a,c,d   Piché, Alain ^a,c,e   Gomez Navarro, Jesús ^a   Wang, Minghui ^a   Alvarez, Ronald D ^a   Siegal, Gene P ^a   Fuller, Gerald M ^b   Jones, Simon A ^b   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF SHERBROOKE   (Canada)

^d Susan G Komen Breast Cancer Foundation   (United States)

^e Institut national du cancer du Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6 RECEPTOR; RECOMBINANT INTERLEUKIN 6;

ADENOVIRUS; ARTICLE; CARCINOMA CELL; CELL KILLING; CELL STRAIN HEPG2; CYTOPATHOGENIC EFFECT; HELA CELL; HUMAN; HUMAN CELL; MESOTHELIUM CELL; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; CARCINOMA, HEPATOCELLULAR; GENE DELETION; GENE THERAPY; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0032948135     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Hermann, F. Cancer gene therapy: principles, problems and perspectives. J. Mol. Med., 73: 157-163, 1995.
2. Schmidt-Wolf, G., and Schmidt-Wolf, I. G. H. Human cancer gene therapy. Ann. Hematol., 69: 273-279, 1994.
3. Culver, K. W., and Blaese, R. M. Gene therapy for cancer. Trends Genet., 10: 174-178, 1994.
4. Freeman, S. M., and Zwiebel, J. A. Gene therapy for cancer. Cancer Invest., 11: 676-688, 1993.
5. Asada, T. Treatment of human cancer with mumps virus. Cancer (Phila.), 34: 1907-1928, 1974.
6. Okono, Y., Asada, T., Yamanishi, K., Otsuka, T., and Takahashi, M. Studies on the use of mumps virus for treatment of human cancer. Biken J., 21: 37-49, 1978.
7. Cassel, W. A., and Garrett, E. Relationship between viral neurotropism and oncolysis. Cancer (Phila.), 20: 433-439, 1967.
8. Pollard, M., and Snyder, C. Treatment of a human cancer case with viruses. Tex. Rep. Biol. Med., 12: 341-344, 1954.
9. Southam, C. M. Viruses in human cancer cell lines m vivo. Virology, 5: 395-400, 1958.
10. Newman, W., and Southam, C. M. Virus treatment in advanced cancer. Cancer (Phila.), 7: 106-118, 1954.
11. Southam, C. M., Hilleman, M. R., and Werner, J. H. Pathogenicity and oncolytic capacity of RI virus strain RI-67 in man. Trans. NY Acad. Sci., 22: 657-673, 1960.
12. Southam, C. M., and Moore, A. Clinical studies of viruses as antineoplastic agents, with particular reference to Egypt 101 virus. Cancer (Phila.), 5: 1025-1034, 1952.
13. Southam, C. M., and Moore, A. E. Induced virus infections in man by the Egypt isolates of west Nile virus. J. Trop. Med. Hyg., 3: 19-50, 1954.
14. Cassel, W. A., and Garrett, R. E. Newcastle disease virus as an antineoplastic agent. Cancer (Phila.), 18: 863-868, 1965.
15. Reichard, K. W., Lorence, R. M., Christopher, J. C., Peeples, M. E., Walter, R. J., Fernando, M. B., Reyes, H. M., and Greager, J. A. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res., 52: 448-453, 1992.
16. Berns, K. I. Parvovirus replication. Microbiol. Rev., 54: 316-329, 1990.
17. Telerman, A., Tuynder, M., Dupressoir, T., Robaye, B., Sigaux, F., Shaulian, E., Oren, M., Rommelaere, J., and Amson, R. A model for tumor suppression using H-1 parvovirus. Proc. Natl. Acad. Sci. USA, 90: 8702-8706, 1993.
18. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. Experimental therapy of human glioma by means of genetically engineered virus mutant. Science (Washington DC), 252: 854-856, 1991.
19. Markert, J. M., Malick, A., Coen, D. M., and Martuza R. L. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery, 35: 597-603, 1993.
20. Mineta, T., Rabkin, S. D., and Martuza, R. L. Treatment of malignant gliomas using ganciclovir-hypersensitive ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res., 54: 3963-3966, 1994.
21. Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B., and Withley R. J. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA , 92: 1411-1415, 1995.
22. Markert, J. M., Coen, D. M. Malick, A., Mineta, T., and Martuza, R. L. Expanded spectrum of viral therapy in the treatment of nervous system tumors. J. Neurosurg., 77: 590-594, 1992.
23. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1: 938-943, 1995.
24. Yazaki, T., Manz, H. J., Rabkin, S. D., and Martuza, R. L. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res., 55: 4752-4756, 1995.
25. Herz, J., and Gerard, R. D. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA, 90: 2812-2816, 1993.
26. Le Gai La Salle, G., Robert, J. J., Berrard, S., Ridoux, V., Stratford-Perricaudet, L. D., Perricaudet, M., and Mallet, J. An adenovirus vector for gene transfer into neurons and glia in the brain. Science (Washington DC), 259: 988-990, 1993.
27. Jaffe, H. A., Danel, C., Longenecker, G., Metzer, M., Setoguchi, Y., Rosenfeld, M. A., Gant, T. W., Thorgeirsson, S. S., Stratford-Perricaudet, L. D., Perricaudet, M., Pavirani, A., Lecocq, J-P., and Crystal, R. G. An adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat. Genet., 1: 372-378, 1992.
28. Spergel, J. M., and Chen-Kiang, S. Interleukin 6 enhances a cellular activity that functionally substitutes for El A protein in transactivation. Proc. Natl. Acad. Sci. USA, 88: 6472-6476, 1991.
29. Spergel, J. M., Hsu, W., Akira, S., Thimmappaya, B., Kishimoto, T., and Chen-Kiang, S. NF-IL-6, a member of the C/EBP family, regulates E1A-responsive promoters in absence of E1A. J. Virol., 66: 1021-1030, 1992.
30. Chen, H-L., Riley, D. J., Chen-Kiang, S., and Lee, W-H. Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL-6. Proc. Natl. Acad. Sci. USA, 93: 465-469, 1996.
31. Graham, F., Smiley, J., Russell, W., and Nair, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36: 59-72, 1977.
32. Weinberg, D. H., and Ketner, G. A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2. Proc. Natl. Acad. Sci. USA, 80: 5383-5386, 1983.
33. Yu, D., Wolf, J. K., Scanlon, M., Price, J. E., and Hung, M-C. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res., 53: 891-898, 1993.
34. Rosenfeld, M. E., Wang, M., Siegal, G. P., Alvarez, R. D., Mikheeva, G., Krasnykh, V., and Curiel, D. T. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J. Mol. Med., 74: 455-462, 1996.
35. Connell, N. D., and Rheinwald, J. G. Regulation of the cytoskeleton in mesothelial cells: reversible loss of keratin and increase in vimentin during rapid growth in culture. Cell, 34: 245-253, 1983.
36. Jones, N., and Shenk, T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell, 17: 683-689, 1979.
37. Bridge, E., and Ketner, G. Redundant control of adenoviruses later gene expression by early region 4. J. Virol., 63: 631-638, 1989.
38. Michiel, D.F., and Oppenheim, J. J. Cylokines as positive and negalive regulalors of tumor promolion and progression. Semin. Cancer Biol., 3: 3-15, 1992.
39. Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. Inlerleukin-6 (IL-6) funclions as an in vitro autocrine growth faclor in renal cell carcinomas. FEES Lett., 250: 607-610, 1989.
40. Tabibzadeh, S. S., Poubouridis, D., May, L. T., and Sehgal, P. B. Interleukin-6 immunoreaclivity in human tumors. Am. J. Pathol., 135: 427-433, 1989.
41. Takenawa, J., Kaneko, Y., Fukumoto, M., Fukatsu, A., Hirano, T., Fukuyama, H., Nakayama, H., Fujita, J., and Yoshida, O. Enhanced expression of interleukin-6 in primary renal carcinomas. J. Natl. Cancer. Inst., 83: 1668-1672, 1991.
42. Eustace, D., Han, X., Gooding, R., Rowbottom, A., Riches, P., and Heyderman, E. Inlerleukin-6 (IL-6) funclions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol. Oncol., 50: 15-19, 1993.
43. Kong, B., Isozaki, T., and Sasaki, S. IL-6 antisense-mediated growth inhibition of a choriocarcinoma cell line: an intracellular autocrine growth mechanism. Gynecol. Oncol., 63: 78-84, 1996.
44. Watson, J. M., Berek, J. S., and Martinez-Maza, O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol. Oncol. 49: 8-15, 1993.
45. Akira, S., Taga, T., and Kishimoto, T. Interleukin-6 in biology and medicine. Adv. Immunol., 54: 1-78, 1993.
46. Lotz, M. Interleukin 6. Cancer Invest., 11: 732-742, 1993.
47. Lahm, H., Petral-Malec, D., Yilmaz-Ceyhan, A., Fischer, J. R., Lorenzoni, M., Givel, J. C., and Odartchenko, N. Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor β1. Eur. J. Cancer, 28A: 1894-1899, 1992.
48. Chen, L., Mory, Y., Zilberstein A., and Revel, M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-β2. Proc. Natl. Acad. Sci. USA, 85: 8037-8041, 1988.
49. Tamm, I., Cardinale, I. Krueger, J., Murphy J. S., May, L. T., and Sehgal, P. B. Interleukin-6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J. Exp. Med., 770: 1649-1669, 1989.
50. Ito, R., Yasui, W., Kuniyasu, H., Yokozaki, H., and Tahara, E. Expression of interleukin-6 and its effect on the cell growth of gastric carcinoma cell lines. Jpn. J. Cancer Res., 88: 953-958, 1997.
51. Okamoto, M., Lee, C., and Oyasu, R. Interleukin-6 as a paracrine and autocrine growth factor in human prostalic carcinoma cells in vitro. Cancer Res., 57: 141-146, 1997.
52. Lu, C., and Kerbel, R. S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell Biol., 720.- 1281-1288, 1993.
53. Borsellino, N., Belldegrun, A., and Bonavida, B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res., 55: 4633-4639, 1995.
54. Sachs, L., and Lotem, J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood, 82: 15-21, 1993.
55. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, A. M. Wild-type p53 induced apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond), 552: 345-347, 1991.
56. Voorzanger, N., Touitou, R., Garcia, E., Delecluse, H-J., Rousset, R., Jaob, I., Favrot, M. C., and Blay, J-Y. Interleukin (IL-)-10 and IL-6 are produced in vivo by non-Hodgkin's Lymphoma cells and act as cooperative growth factors. Cancer Res., 56: 5499-5505, 1996.
57. Obata, N. H., Tamakoshi, K., Shibata, K., Kikkawa, F., and Tomoda, Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res., 17: 337-342, 1997.
58. Li, B. Y., Mohanraj, D., Olson, M. C., Moradi, M., Twiggs, L., Carson, L. F., and Ramakrishnan, S. Human ovarian epithelial cells cultures in vitro express both interleukin 1 α and β genes. Cancer Res. 52: 2248-2252, 1992.
59. Moradi, M. M., Carson, L. F., Weinberg B., Haney, A. F., Twiggs, L. B., and Ramakrishnan, S. Serum and ascitic fluid levels on interleukin-1, interleukin-6 and tumor necrosis factor-α in patients with ovarian epithelial cancer. Cancer (Phila.), 72: 2433-2440, 1993.
60. Burger, R. A., Grosen, E. A., Ioli, G. R., Van Eden, M. E., Park, M., Berman, M. L., Manetta, A., Disaia, P. J., Granger, G. A., and Gatanaga, T. Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cells populations purified from human ovarian carcinoma. J. Interferon Cytokine Res., 75: 255-260, 1995.
61. Berek, J. S., Chung, C., Kaldi, K., Watson, J. M., Knox, R. M., and Martinez-Maza, O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol., 164: 1038-1042, 1991.
62. Scambia, G., Testa, U., Benedetti-Pacini, P., Foti, E., Martuzi, R., Gadducci, A., Perillo, A., Facchini, V., Peschle, C., and Mancuso, S. Prognostic significance of interleukin-6 serum levels in patients with ovarian cancer. Br. J. Cancer 71: 354-356, 1995.
63. Tempfer, C., Zeisler, H., Sliutz, G., Haeusler, G., Hanzal, E., and Kainz, C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol. Oncol., 66: 27-30, 1997.
64. Smith, R. R., Huebner, R. J., Rowe, W. P., Schatten, W. E., and Thomas, L. B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer (Phila.), 9: 1211-1218, 1956.
65. Bischoff, J. R., Kim, D. H., Williams, A., Heise C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick F. An adenovirus mutant that selectively replicates in p53-deficient human tumor cells. Science (Washington DC), 274: 373-376, 1996.
66. Rodrigues, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57: 2559-2563, 1997.
67. Crystal, R. G., McElvaney, N. G., Rosenfeld, M. A., Chu, C. S., Mastrangeli, A., Hay, J. G., Brody, S. L., Jaffe, H. A., Eissa, N. T., and Danel, C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis (see comments). Nat. Genet., 8: 42-51, 1994.